Alternative dosing of omalizumab as an adjunct therapy during multiallergen oral immunotherapy in food allergic patients

Adjunct therapy with omalizumab in multiallergen oral immunotherapy (mOIT) trials is typically dosed based on the FDA approved asthma dosing guidelines targeting a monthly dose of at least 0.016mg/kg/(IU/mL). However, dose-finding studies have yet to be performed to provide guidance on the minimum dose necessary for food allergy.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2MS5L0B